Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study)
Clinical trial NCT05710666 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05710666
- Sponsor
- Cancer Trials Ireland
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-10-26
- Primary completion
- 2025-09-30
- Enrollment
- 11
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.